

ODJFS P&T Committee Meeting

April 23, 2008

9:00 AM

Riffe Building, Room 1948, 77 S. High St., Columbus

Agenda

A. Drugs under consideration

1. Bystolic (nebivolol), Forest
2. Azor (amlodipine/olmesartan), Daiichi Sankyo
3. Lipofen (fenofibrate), ProEthic

B. Preferred Drug List (PDL) progress report

C. Discussion of new 2008 PDL drug classes

New classes:

Antidepressants

Antipsychotics, Second Generation

Anti-Rheumatic Agents, Injectable

Growth Hormones

Ophthalmic antibiotics (expanded from ophthalmic quinolones)

Ophthalmic NSAIDs

Pancreatic Enzymes

Parkinson's Agents

Post-Herpetic Neuralgia, Topical Agents

D. Clinical utilization criteria for PDL drug classes

Criteria discussion for October 2008 implementation

Heparin-Related Preparations, duration of use limited to 35 days